Innovation in European healthcare – what can Sweden learn? - LIF

Hospitals carry out more and more outpatient activities
which increase the inpatient drug market for outpatients
• Inpatient market represents an increasing
share of the total market
• 8% growth of the inpatient market since
1999
• In 2009, it represents 20% of the total
French pharmaceutical market. This
share doubled in 20 years.
The 3 segments of the inpatient drugs' market
Total: EUR 5.75 billion
Retrocession
List
25%
Not-included
in GHS (list of
reimbursed
drugs)
44%
GHS Tariffs
31%
The inpatient market is divided into 3
segments:
• Drugs included in the different GHS tariffs
– High competition, mostly among generics
– Stable expenditures
• Expensive drugs excluded from GHS
(real-cost payments). On the list of
Reimbursed Drugs:
– Mostly innovative drugs
– Increasing share of total drugs
expenditures
• Drugs that hospitals can provide to
outpatients : on the “retrocession” list
– Mostly innovative drugs, no competition
with generics
– Prices fixed by national authorities
– The 2005 reform stopped the rapid growth
of expenditures: drugs made available in
private pharmacies
91